Life-changing Alzheimer's drug approved for use in EU to reduce cognitive decline
A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, which is given via an intravenous drip every two weeks, has been proven in clinical trials to decrease amyloid plaques. It has also already been given the green light for use in the UK.
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Researchers have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer's genesis and progression. The proteins were gathered from cerebrospinal ...
Officials said over 71,000 Oklahomans are currently living with Alzheimer's disease. Nationally, that number is approaching 7 ...
3don MSNOpinion
Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...
12hOpinion
November is Alzheimer’s Awareness Month and New York has the second highest rate of Alzheimer’s disease in the U.S. NYC’s ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback